Used in combination with trifluridine for the treatment of metastatic colorectal cancer and metastatic gastric cancer. The compound enhances the bioavailability of trifluridine by inhibiting its degradation enzyme, thymidine phosphorylase, thereby increasing the drug's exposure in tumor cells. This combination therapy is typically reserved for patients who have progressed after standard treatments, offering a palliative option to extend survival.